NICE Recommends Astellas' EVRENZO▼™ (roxadustat) For Adults With Symptomatic Anaemia Associated With Chronic Kidney Disease

NICE Recommends Astellas’ EVRENZO▼™ (roxadustat) For Adults With Symptomatic Anaemia Associated With Chronic Kidney Disease EVRENZOTM (roxadustat) is the first hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor to be recommended by NICE1Over 75,000 adults in England and Wales living with...

Related Keywords

United Kingdom ,Japan ,Shutov ,Orenburgskaya Oblast ,Russia ,United States ,Besarab ,Belgorodskaya Oblast ,New Zealand ,Washington ,China ,South Africa ,Chile ,South Korea ,Northern Ireland ,Craigavon ,Turkey ,Great Britain ,American ,Kenji Yasukawa ,Andrea Brown ,Research Partnerships ,Kidney International ,Renal Association Clinical Practice Guideline ,Astellas Pharma Ltd ,Pr Market Research ,National Kidney Federation ,National Institute For Health ,Astellas Pharma Inc ,Tissue Transplantation Services Professional Advisory Committee ,Astrazeneca ,National Kidney Foundation ,American Society Of Nephrology ,National Institue ,Astellas Pharma ,National Institute ,Care Excellence ,Chief Executive ,Medical Director ,Astellas United Kingdom ,Independent States ,Middle East ,European Summary ,Product Characteristics ,Electronic Medicines Compendium United Kingdom ,Pharma Inc ,Focus Area Approach ,Appraisal Document ,Nobel Prize ,Chronic Kidney ,Incident Dialysis ,Inducible Factor Prolyl Hydroxylase Inhibitors ,Potential New Treatment ,Patients With ,Appraisal Documnet ,Atherosclerosis Risk ,Rev Nephrol ,Nephrol Dial Transplant ,Maintenance Treatment ,End Stage Kidney Disease ,Stable Dialysis ,European Phase ,Active Controlled Study ,Adv Ther ,Dial Transplant ,American Society ,Annual Meeting ,Kidney Int Rep ,Treating Anemia ,Randomized Phase ,Chronic Kidney Disease ,Cardiovasc Med ,Med Prim Care ,Blood Transfusion ,Practice Guideline ,